Molecular Detection of Toxoplasmosis among Patients in Holly Karbala Province, Iraq

Abstract

   The current study was conducted in November 2023. 150 samples of malignant breast cancer tissue embedded in paraffin wax and diagnosed by a specialist doctor were collected, and 50 samples of benign tumor tissue It was used as a control group; these samples were collected from the tissue cutting laboratory in Imam Hussein Medical City, Al-Kafeel Specialized Hospital laboratory, and the specialized AL-Sajad laboratory for histological and cellular examinations and tumor diagnosis in Holy Karbala. The study samples included two groups. The first group consisted of 66 women with breast cancer who did not undergo chemotherapy; the second group was 84 women with breast cancer who underwent chemotherapy. PCR technology was performed on DNA in tissue samples affected by breast cancer for all groups under study, based on the amplification of the B1, SAG1, gene; the current study aimed to determine the incidence of toxoplasmosis in breast cancer patients. The incidence of toxoplasmosis in breast cancer patients was 11.3%, and the infection rate in the healthy group was 4%. The results showed that the infection rate in women who received treatment was higher than in women who did not receive treatment due to weakness, their immunity, and the risk of infection, increasing the probability of sick women developing breast cancer by 3.7% compared to healthy women.